Myeloid Leukemia

More documents

Recommendations

Info

Contributors TANYA L. APPLEGATE • Johnson & Johnson Research Pty. Limited, NSW, Australia NICOLE BARBER • School of Molecular and Microbial Biosciences, University of Sydney, NSW, Australia E. JOANNA BAXTER • Department of Haematology, University of Cambridge, Cambridge, UK LARISSA BELOV • School of Molecular and Microbial Biosciences, University of Sydney, NSW, Australia ANTHONY J. BENCH • Department of Haematology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK LINDA BENDALL • Westmead Institute for Cancer Research, Westmead Millennium Institute, Westmead, NSW, Australia ANDREA BIONDI • Centro Ricerca M. Tettamanti, Clinica Pediatrica Università di Milano Bicocca and Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Ospedale San Gerardo, Monza, Italy SUSAN BRANFORD • Division of Molecular Pathology, Institute of Medical and Veterinary Science, South Australia, Australia LYNDA J. CAMPBELL • Cytogenetics Department, St. Vincent’s Hospital, Victoria, Australia PETER J. CAMPBELL • Department of Haematology, University of Cambridge, Cambridge, UK RICHARD I. CHRISTOPHERSON • School of Molecular and Microbial Biosciences, University of Sydney, NSW, Australia DANIELA CILLONI • Department of Clinical and Biological Sciences, University of Turin, Turin, Italy JAN COOLS • Department of Human Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), University of Leuven, Leuven, Belgium WENDY N. ERBER • Department of Haematology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK CAROLINE J. FUERY • Johnson & Johnson Research Pty. Limited, NSW, Australia JEAN GABERT • Department of Biochemistry & Molecular Biology, Hôpital Universitaire Nord (AP-HM), ERT-MEIDIA-IFR Jean Roche-Université de la Méditerranée, Marseille, France ix
x Contributors D. GARY GILLILAND • Brigham and Women’s Hospital, Harvard Medical School, and Howard Hughes Medical Institute, Harvard University, Boston, Massachusetts ENRICO GOTTARDI • Department of Clinical and Biological Sciences, University of Turin, Turin, Italy ANTHONY R. GREEN • Department of Haematology, University of Cambridge, and Department of Haematology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK TORSTEN HAFERLACH • Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-University, Munich, Germany WOLFGANG HIDDEMANN • Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-University, Munich, Germany TIMOTHY HUGHES • Division of Hematology, Institute of Medical and Veterinary Science, South Australia, Australia JOOP H. JANSEN • Central Hematology Laboratory, University Medical Center St. Raboud, The Netherlands WOLFGANG KERN • Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-University, Munich, Germany HITOSHI KIYOI • Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan ALEXANDER KOHLMANN • Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig-Maximilians-University, Munich, Germany LUIGI M. LAROCCA • Instituto di Anatomia Patologica and Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy LAURA LEVATI • Centro Ricerca M. Tettamanti, Clinica Pediatrica Università di Milano Bicocca and Dipartimento di Medicina Clinica, Prevenzione e Biotecnologie Sanitarie, Ospedale San Gerardo, Monza, Italy THOMAS LION • Children’s Cancer Research Institute (CCRI), Vienna, Austria MAURIZIO MARTINI • Instituto di Anatomia Patologica and Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy ELISA MOKANY • Johnson & Johnson Research Pty. Limited, NSW, Australia STEPHEN P. MULLIGAN • School of Molecular and Microbial Biosciences, University of Sydney, NSW, Australia TOMOKI NAOE • Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Page 1 and 2: M E T H O D S I N M O L E C U L A R
Page 3 and 4: M E T H O D S I N M O L E C U L A R
Page 5 and 6: © 2006 Humana Press Inc. 999 River
Page 7 and 8: vi Preface comprehensive review of
Page 9: viii Contents 11 Detection of the F
Page 14 and 15: RNA and DNA From Leukocytes 1 1 Iso
Page 16 and 17: RNA and DNA From Leukocytes 3 mine
Page 18 and 19: RNA and DNA From Leukocytes 5 late
Page 20 and 21: RNA and DNA From Leukocytes 7 9. Us
Page 22 and 23: RNA and DNA From Leukocytes 9 16. C
Page 24 and 25: RNA and DNA From Leukocytes 11 3. I
Page 26 and 27: Cytogenetic and FISH Techniques 13
Page 40 and 41: Real-Time RT-PCR Strategies 27 3 Ov
Page 42 and 43: Real-Time RT-PCR Strategies 29
Page 44 and 45: Real-Time RT-PCR Strategies 31 cifi
Page 46 and 47: Real-Time RT-PCR Strategies 33 2.1.
Page 48 and 49: Real-Time RT-PCR Strategies 35 Fig.
Page 50 and 51: Real-Time RT-PCR Strategies 37 2.1.
Page 52 and 53: Real-Time RT-PCR Strategies 39 the
Page 54 and 55: Real-Time RT-PCR Strategies 41 Fig.
Page 56 and 57: Real-Time RT-PCR Strategies 43 duri
Page 58 and 59: MyiQ single color 400 nm 585 nm 96
Page 60 and 61:
Real-Time RT-PCR Strategies 47 side
Page 62 and 63:
Table 2 Real-Time Quantitative Poly
Page 64 and 65:
Real-Time RT-PCR Strategies 51 AML-
Page 66 and 67:
Real-Time RT-PCR Strategies 53 the
Page 68 and 69:
Real-Time RT-PCR Strategies 55 plas
Page 70 and 71:
Real-Time RT-PCR Strategies 57 betw
Page 72 and 73:
Real-Time RT-PCR Strategies 59 Ct C
Page 74 and 75:
Real-Time RT-PCR Strategies 61 Fig.
Page 76 and 77:
Real-Time RT-PCR Strategies 63 asse
Page 78 and 79:
Real-Time RT-PCR Strategies 65 21.
Page 80 and 81:
Real-Time RT-PCR Strategies 67 50.
Page 82 and 83:
Quantitative PCR for Monitoring CML
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Detection of BCR-ABL Mutations 93 5
Page 108 and 109:
Detection of BCR-ABL Mutations 95 F
Page 110 and 111:
Detection of BCR-ABL Mutations 97 2
Page 112 and 113:
Detection of BCR-ABL Mutations 99 o
Page 114 and 115:
Detection of BCR-ABL Mutations 101
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Deletion of Derivative Chromosome 9
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Diagnosis of PML-RARA-Positive APL
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Duplexed QZyme RT-PCR for APL Analy
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Diagnosis of AML1-MTG8 (ETO)-Positi
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Diagnosis of CBFB-MYH11-Positive AM
Page 178 and 179:
165 Table 1 Primers for CBFB-MYH11
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
FIP1L1-PDGFRA in Hypereosinophilic
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
FLT3 Mutations in AML 189 12 FLT3 M
Page 204 and 205:
FLT3 Mutations in AML 191 3.1.1. DN
Page 206 and 207:
FLT3 Mutations in AML 193 Table 2 R
Page 208 and 209:
FLT3 Mutations in AML 195 Fig. 2. D
Page 210 and 211:
FLT3 Mutations in AML 197 10. Kiyoi
Page 212 and 213:
WT1 Expression in AML and MDS 199 1
Page 214 and 215:
WT1 Expression in AML and MDS 201 T
Page 216 and 217:
Page 218 and 219:
WT1 Expression in AML and MDS 205 T
Page 220 and 221:
WT1 Expression in AML and MDS 207 F
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Classification of AML by DNA-Oligon
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
233 Classification of AML by DNA-Ol
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Classification of AML by Monoclonal
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
247 Classification of AML by Monocl
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Detecting JAK2 V617F Mutation in MP
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
PRV-1 Overexpression in PV and ET 2
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Chimerism Analysis 275 18 Chimerism
Page 290 and 291:
Chimerism Analysis 277 1.2. Detecti
Page 292 and 293:
Chimerism Analysis 279 3. Extractio
Page 294 and 295:
Chimerism Analysis 281 14. 310 Gene
Page 296 and 297:
Chimerism Analysis 283 12. Upon com
Page 298 and 299:
Chimerism Analysis 285 Fig. 2. Calc
Page 300 and 301:
Chimerism Analysis 287 4. Allow the
Page 302 and 303:
Chimerism Analysis 289 capillary el
Page 304 and 305:
Chimerism Analysis 291 and recipien
Page 306 and 307:
Chimerism Analysis 293 Table 2 Comm
Page 308:
Chimerism Analysis 295 12. Maas, F.
Page 311 and 312:
298 Index management, 128 AML, see
Page 313 and 314:
300 Index and AML, 213, 236, 238, 2
Page 315 and 316:
302 Index chimerism analysis in sex
Page 317 and 318:
304 Index minimal residual disease
Page 319:
306 Index Stem cell transplantation
show all

Myeloid Leukemia

Create successful ePaper yourself

Delete template?

Save as template?